Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles W Carroll

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Genome Biology|March 14, 2023
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infectionHannah Goldswain, Xiaofeng Dong, Rebekah Penrice-Randal, et al.
Plos Pathogens|January 13, 2022
Advances and gaps in SARS-CoV-2 infection modelsCésar Muñoz-Fontela, Lina Widerspick, Randy A Albrecht, et al.
Nature Protocols|May 25, 2017
Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samplesJoshua Quick, Nathan D Grubaugh, Steven T Pullan, et al.
Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2016
Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 DaysBoubacar Diallo, Daouda Sissoko, Nicholas J Loman, et al.
Lancet (London, England)|December 27, 2016
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini, et al.
Nature Communications|September 23, 2021
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19Jiandong Huo, Halina Mikolajek, Audrey Le Bas, et al.
Nature Communications|August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
Clinical and Experimental Immunology|April 20, 2024
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recoveryMohammad Ali, Stephanie Longet, Isabel Neale, et al.
Nature Structural & Molecular Biology|October 16, 2020
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiangdong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Genome Biology|March 14, 2023
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infectionHannah Goldswain, Xiaofeng Dong, Rebekah Penrice-Randal, et al.
Plos Pathogens|January 13, 2022
Advances and gaps in SARS-CoV-2 infection modelsCésar Muñoz-Fontela, Lina Widerspick, Randy A Albrecht, et al.
Nature Protocols|May 25, 2017
Multiplex PCR method for MinION and Illumina sequencing of Zika and other virus genomes directly from clinical samplesJoshua Quick, Nathan D Grubaugh, Steven T Pullan, et al.
Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2016
Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 DaysBoubacar Diallo, Daouda Sissoko, Nicholas J Loman, et al.
Lancet (London, England)|December 27, 2016
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini, et al.
Nature Communications|September 23, 2021
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19Jiandong Huo, Halina Mikolajek, Audrey Le Bas, et al.
Nature Communications|August 18, 2021
Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concernDonal T Skelly, Adam C Harding, Javier Gilbert-Jaramillo, et al.
Clinical and Experimental Immunology|April 20, 2024
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recoveryMohammad Ali, Stephanie Longet, Isabel Neale, et al.
Nature Structural & Molecular Biology|October 16, 2020
Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2Jiangdong Huo, Audrey Le Bas, Reinis R Ruza, et al.
Pageof 15